SWTX's desmoid tumor drug, Ogsiveo, is driving its top line. The recent FDA nod for Gomekli to treat a rare tumor diversifies its commercial portfolio.

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

Over the last 7 days, the United States market has dropped by 4.4%, yet it has risen by 7.5% over the past year, with earnings forecasted to grow by 14% annually. In this environment, identifying high ...

Our analysis of options history for SpringWorks Therapeutics SWTX revealed 9 unusual trades. Delving into the details, we ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Ogsiveo's net product revenues were $172 million in 2024. Last month, the FDA approved SpringWorks’ MEK inhibitor, Gomekli (mirdametinib) for the treatment of adult and pediatric patients 2 ...

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Candel Therapeutics (CADL – Research ...

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Meiragtx Holdings (MGTX – Research Report) today and set a price ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

Oppenheimer Asset Management Inc. lessened its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 6.2% in ...

SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biotechnology company focused on developing targeted therapies for patients with severe rare diseases and cancer, has been garnering attention in ...